Icu medical chief financial officer Brian Bonnell sells $1.1 million in stock By Investing.com

Brian Bonnell, Chief Financial Officer of ICU Medical Inc. (), sold 6,381 shares of the company’s common stock on September 1, 2026. The shares were sold at a price of $175.00 per share, totaling $1,116,675.

The transaction was executed pursuant to a Rule 10b5-1 trading plan, which Bonnell adopted on June 1, 2026. All shares in this reported sale were sold at the exact price disclosed.The sale comes as ICU Medical shares trade at $170.81, up 34% over the past year. According to InvestingPro analysis, the stock appears undervalued with a Fair Value of $180.72, suggesting potential upside. The platform reveals that 6 analysts have recently revised their earnings upwards, with price targets ranging from $178 to $210.

Following this transaction, Bonnell directly holds 56,062 shares of ICU Medical common stock.

In other recent news, ICU Medical reported second-quarter adjusted earnings and revenue that exceeded Wall Street forecasts. The company announced an adjusted EPS of $2.37, surpassing the expected $1.91, and revenue of $548 million, which was higher than the projected $533.4 million. Additionally, ICU Medical raised its full-year adjusted EPS guidance to a range of $8.60 to $9, up from the previous $7.75 to $8.45. Adjusted EBITDA guidance was also increased, indicating confidence in future performance.

In another development, S&P Global Ratings upgraded ICU Medical’s credit rating to ’BB’ from ’BB-’, citing strengthened credit metrics and solid operating performance. This upgrade reflects the company’s successful leverage reduction, with reported leverage decreasing to 2.28x as of June 30, 2026. ICU Medical utilized approximately $250 million to repay debt, contributing to this improvement.

Furthermore, Raymond James raised its price target for ICU Medical stock to $200 from $180 while maintaining a Strong Buy rating. The firm highlighted the company’s overall revenue growth, particularly in Infusion Systems, which saw double-digit growth despite some challenges. These recent developments underscore ICU Medical’s positive financial trajectory and strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.